Drug intelligence / Profile preview

JWK001

Development stage: Phase 2
Lead developer: Chengdu Genevector Biotechnology
Modality: Gene Therapies
Administration: Subretinal

Overview

JWK001 is an adeno-associated virus (AAV)-based gene therapy developed by Jinweike Bio for the treatment of neovascular ophthalmic diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The therapy utilizes a proprietary two-plasmid packaging system to deliver a transgene encoding a novel anti-vascular endothelial growth factor (VEGF) protein directly into retinal cells. This approach aims to achieve sustained expression of the therapeutic protein, thereby suppressing abnormal blood vessel growth and leakage while reducing the burden of frequent intravitreal injections. JWK001 received IND approval from China's NMPA for DME in March 2026 and is currently in clinical development.

Other names: JWK001注射液

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on JWK001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JWK001.

Explore the full profile